Posted by Michael Wonder on 24 Sep 2020
GW Pharmaceuticals receives Australian Therapeutic Goods Administration approval for Epidyolex (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy
23 September 2020 - This represents the third successful regulatory approval globally for GW’s plant-derived cannabis-based medicine.
GW Pharmaceuticals today announces that the Australian TGA has approved Epidyolex (cannabidiol) for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients two years of age and older.
The approval of GW’s cannabidiol is based on results from four randomised, controlled Phase 3 clinical trials.
